Genmab Current Deferred Revenue vs Short Long Term Debt Total Analysis
| GMAB Stock | USD 21.30 0.38 1.82% |
Genmab AS financial indicator trend analysis is much more than just examining Genmab AS latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Genmab AS is a good investment. Please check the relationship between Genmab AS Current Deferred Revenue and its Short Long Term Debt Total accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.
Current Deferred Revenue vs Short Long Term Debt Total
Current Deferred Revenue vs Short Long Term Debt Total Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Genmab AS Current Deferred Revenue account and Short Long Term Debt Total. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Genmab AS's Current Deferred Revenue and Short Long Term Debt Total is -0.24. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Short Long Term Debt Total in the same time period over historical financial statements of Genmab AS, assuming nothing else is changed. The correlation between historical values of Genmab AS's Current Deferred Revenue and Short Long Term Debt Total is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Genmab AS are associated (or correlated) with its Short Long Term Debt Total. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt Total has no effect on the direction of Current Deferred Revenue i.e., Genmab AS's Current Deferred Revenue and Short Long Term Debt Total go up and down completely randomly.
Correlation Coefficient | -0.24 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Short Long Term Debt Total
Most indicators from Genmab AS's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Genmab AS current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.At present, Genmab AS's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Tax Provision is expected to grow to about 1.6 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.07.
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Expense | 21M | 27M | 24.3M | 16.6M | Depreciation And Amortization | 290M | 240M | 276M | 289.8M |
Genmab AS fundamental ratios Correlations
Click cells to compare fundamentals
Genmab AS Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Genmab AS fundamental ratios Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 21.1B | 24.6B | 30.3B | 35.3B | 40.6B | 42.6B | |
| Short Long Term Debt Total | 319M | 425M | 597M | 770M | 885.5M | 929.8M | |
| Other Current Liab | 1.1B | 1.2B | 1.7B | 2.3B | 2.7B | 2.8B | |
| Total Current Liabilities | 1.3B | 1.6B | 1.8B | 2.5B | 2.9B | 3.0B | |
| Total Stockholder Equity | 19.1B | 22.2B | 27.4B | 31.6B | 36.4B | 38.2B | |
| Property Plant And Equipment Net | 736M | 975M | 1.3B | 1.6B | 1.9B | 2.0B | |
| Net Debt | (6.9B) | (8.5B) | (9.3B) | (14.1B) | (12.7B) | (12.1B) | |
| Retained Earnings | 7.1B | 10.0B | 15.0B | 19.0B | 21.9B | 23.0B | |
| Accounts Payable | 145M | 350M | 1.7B | 2.3B | 2.7B | 2.8B | |
| Cash | 7.3B | 9.0B | 9.9B | 14.9B | 17.1B | 18.0B | |
| Non Current Assets Total | 2.4B | 1.9B | 1.9B | 2.2B | 2.5B | 2.6B | |
| Non Currrent Assets Other | 20M | 27M | 48M | 274M | 246.6M | 343.6M | |
| Cash And Short Term Investments | 16.1B | 19.3B | 22.3B | 28.1B | 32.4B | 34.0B | |
| Common Stock Shares Outstanding | 65.9M | 66.0M | 66.0M | 65.9M | 59.3M | 56.4M | |
| Liabilities And Stockholders Equity | 21.1B | 24.6B | 30.3B | 35.3B | 40.6B | 42.6B | |
| Non Current Liabilities Total | 769M | 863M | 1.0B | 1.2B | 1.4B | 1.4B | |
| Other Current Assets | 10.4B | 249M | 31M | 143M | 164.5M | 156.2M | |
| Other Stockholder Equity | 11.9B | 12.0B | 12.2B | 12.5B | 14.3B | 7.6B | |
| Total Liab | 2.0B | 2.4B | 2.8B | 3.7B | 4.2B | 4.4B | |
| Property Plant And Equipment Gross | 736M | 1.3B | 1.8B | 2.3B | 2.7B | 2.8B | |
| Total Current Assets | 18.8B | 22.7B | 28.4B | 33.1B | 38.1B | 40.0B | |
| Short Term Debt | 42M | 62M | 74M | 90M | 103.5M | 108.7M | |
| Intangible Assets | 338M | 254M | 146M | 101M | 116.2M | 192.7M | |
| Short Term Investments | 8.8B | 10.4B | 12.4B | 13.3B | 15.3B | 16.0B | |
| Net Receivables | 2.5B | 3.4B | 5.7B | 4.9B | 5.7B | 6.0B | |
| Inventory | (249M) | (31M) | (143M) | 57M | 51.3M | 53.9M | |
| Accumulated Other Comprehensive Income | 98M | 54M | 81M | 60M | 69M | 56.5M | |
| Net Tangible Assets | 13.6B | 18.8B | 21.9B | 27.3B | 31.4B | 33.0B | |
| Other Assets | 150M | 197M | 291M | 300M | 345M | 243.7M | |
| Capital Lease Obligations | 319M | 425M | 597M | 770M | 885.5M | 929.8M | |
| Long Term Investments | 1.1B | 371M | 133M | 134M | 154.1M | 228.3M | |
| Property Plant Equipment | 414M | 736M | 975M | 1.3B | 1.5B | 1.6B | |
| Net Invested Capital | 19.1B | 22.2B | 27.4B | 31.6B | 36.4B | 20.2B | |
| Net Working Capital | 17.5B | 21.2B | 26.6B | 30.7B | 35.3B | 19.1B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 4.634 | Earnings Share 1.69 | Revenue Per Share | Quarterly Revenue Growth 0.353 | Return On Assets |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.